4Suppliers
12Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Replimune Group, Inc. (REPL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships
2Distinct source URLs
7High confidence
0.763Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Replimune Group, Inc. Suppliers

TickerNameConfidenceEvidence
HTGC Hercules Capital, Inc. 90% Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: the Company, Hercules, and the Lend…
HTGC Hercules Capital, Inc. 90% the Company, Hercules, and the Lenders agreed to amend the Loan and Security Agreement
ROCHE ROCHE 90% The ongoing study in HCC is being developed in combination with atezolizumab and bevacizumab under a supply and clinical collaboration agreement with Roche.
GNLX Genelux Corporation 72% Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…

Replimune Group, Inc. Customers

TickerNameConfidenceEvidence
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from REPL graph: the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock o…
BMY Bristol-Myers Squibb Company 72% the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMYMP Bristol-Myers Squibb Co 72% the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from REPL graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from REPL graph: the Company's common stock, and 3…
GNLX Genelux Corporation 72% Reciprocal relationship from GNLX graph: Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX g…
HTGC Hercules Capital, Inc. 72% rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or declining economy or political disruptio…
HTGC Hercules Capital, Inc. 72% Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate m…
INTS Intensity Therapeutics, Inc. 72% Reciprocal relationship from INTS graph: Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are d…
IRELAND-LIMITED IRELAND-LIMITED 62% (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% complex and continue to evolve. There can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damagi…
REPLIMUNE-SECURITIES-CORPORATION REPLIMUNE-SECURITIES-CORPORATION 62% (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…
REPLIMUNE-UK-REPLIMUNE-US-REPLIMUNE-SECURITIES-C REPLIMUNE-UK-REPLIMUNE-US-REPLIMUNE-SECURITIES-C 62% (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…

Replimune Group, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
REPL-DEBT-12132 Warrants outstanding: 5284238 90% xbrl warrant detail from xbrl 2022-03-31.
REPL-DEBT-12133 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-03-31.
REPL-DEBT Debt stack $84.1M 90% Market cache reports total debt of $84.1M.

Replimune Group, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Replimune Group, Inc..

Replimune Group, Inc. Ownership

HolderNameConfidenceEvidence
REPL-OWNER-BAKER-BROS-ADVISORS-LP BAKER BROS. ADVISORS LP 90% 13F overlay lists BAKER BROS. ADVISORS LP as top holder; 187 tracked holders.

Replimune Group, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CMPS COMPASS Pathways plc 100.00 2
DRTS Alpha Tau Medical Ltd. 100.00 2
ALEC Alector, Inc. 100.00 2
ATON AlphaTON Capital Corp 100.00 2
GNLX Genelux Corporation 100.00 1 ['customer', 'supplier']
BCYC Bicycle Therapeutics plc 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
TLSA Tiziana Life Sciences Ltd 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CLLS Cellectis S.A. 100.00 2
IRON Disc Medicine, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
🔐
REPL
Unlock REPL Supply Chain Data
Verified relationships include:
HTGCHercules Capital, Inc.Supplier90%
HTGCHercules Capital, Inc.Supplier90%
BMYBristol-Myers Squibb CompanyCustomer72%
BMYBristol-Myers Squibb CompanyCustomer72%
+16 more relationships locked
Subscribe — View plans →